China’s SAMR Continues Focus on Pharma Sector Amid Covid-19 Outbreak, Fining API Distributors Over RMB300m for Abuse of Dominance

On 9 April 2020, China’s State Administration for Market Regulation (SAMR) fined 3 pharmaceutical companies for abuse of dominance in the distribution of injectable calcium gluconate Active Pharmaceutical Ingredient (API). The three companies were found to be in breach of the PRC’s Anti-Monopoly Law (the AML) between August 2015 and December 2017, by selling at … Read more